35144-22-0

Basic information

• Product Name: 4,6-Dimethyl-2-methylsulfonylpyrimidine
• Synonyms: VITAS-BB TBB000242;DLMSP;4,6-DIMETHYL-2-METHYLSULFONYLPYRIMIDINE;4,6-DIMETHY-2-METHYLSULFONYLPYRIMIDINE;2-METHANESULFONYL-4,6-DIMETHYL-PYRIMIDINE;4,6-dimethyl-2-mesyl-pyrimidine;4,6-Dimethyl-2-methylsilfonylpyrimidine;4,6-Dimethyl-2-(methylsulfonyl
• CAS NO: 35144-22-0
• Molecular Formula: C₇H₁₀N₂O₂S
• Molecular Weight: 186.23
• EINECS: 1592732-453-0
• Product Categories: Boron, Nitrile, Thio,& TM-Cpds;Heterocycles;Pyrimidines;Drug Intermediates;Heterocycle-Pyrimidine series;Intermediate
• Mol File: 35144-22-0.mol

Chemical Properties

• Melting Point: 84-86°C
• Boiling Point: 358.3 °C at 760 mmHg
• Flash Point: 170.5 °C
• Appearance: Red-brown/Crystalline Solid
• Density: 1.239
• Vapor Pressure: 5.32E-05mmHg at 25°C
• Refractive Index: 1.511
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: -1.84±0.30(Predicted)
• CAS DataBase Reference: 4,6-Dimethyl-2-methylsulfonylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dimethyl-2-methylsulfonylpyrimidine(35144-22-0)
• EPA Substance Registry System: 4,6-Dimethyl-2-methylsulfonylpyrimidine(35144-22-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 35144-22-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,6-Dimethyl-2-methylsulfonylpyrimidine is used as a reactant for the preparation of [(dimethylpyrimidinyl)oxy]diphenyl butyric acid derivatives, which are known as endothelin receptor antagonists. These antagonists play a crucial role in treating various cardiovascular and respiratory diseases by blocking the action of endothelin, a potent vasoconstrictor peptide.

InChI:InChI=1/C7H10N2O2S/c1-5-4-6(2)9-7(8-5)12(3,10)11/h4H,1-3H3

Upstream product

• 14001-64-0 4,6-dimethyl-2-methylsulfanyl-pyrimidine 
• 22325-27-5 4,6-dimethyl-2-meraptopyrimidine 

Downstream Products

• 22746-09-4 4,6-dimethyl-2-(piperazin-1-yl)pyrimidine 
• 1240470-84-1 (S)-methyl-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionate 
• 204267-33-4 Lu 224332 
• 204267-33-4 Feloprentan 

Relevant articles and documents

Oxidative kinetic resolution of heterocyclic sulfoxides with a porphyrin-inspired manganese complex by hydrogen peroxide

We have successfully reported here the low loading porphyrin-inspired high-valent manganese (IV)-oxo complex was applied in oxidative kinetic resolution (OKR) of racemic heterocyclic sulfoxides using the environmentally benign hydrogen peroxide for the first time. This approach allows for rapid OKR (0.5 h) of a variety of racemic sulfoxides (including pyridine, pyrimidine, pyrazine, thiazole, benzothiazole, thiophene) in excellent enantioselectivity (up to > 99% ee), simultaneously generating the corresponding sulfones in high yield (up to 80%). The catalytic system also showed an unexceptionable chemoselectivity for the sulfoxide substrates with hydroxyl groups in which only the sulfoxide group was oxidized. The practical utility of the method has been demonstrated in the OKR of gram-scale sulfoxides.

Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists

Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ET A/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo[e] [1,4]diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.

Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists

The invention relates to carboxylic acid derivatives of the formula I where the radicals have the meanings stated in the description, and to their use as drugs.

Herbicidal 2-(phenoxy or phenylthio)-2-(pyrimidinyloxy or 1,3,5-triazinyloxy)-alkanoic acids

2-(Phenoxy or phenylthio)-2-(pyrimidinyloxy or 1,3,5-triazinyloxy)alkanoic acid compounds, such as ethyl 2-(2-fluorophenoxy)-2-(4,6-dimethylpyrimidin-2-yl-oxy)acetate, were prepared by the reaction of a phenol or thiophenol compound with a 2-chloro-2-(pyrimidinyloxy or 1,3,5-triazinyloxy)alkanoate ester compound or by the reaction of a pyrimidinol or 1,3,5-triazinol with a 2-bromo-2-(phenoxy or phenylthio)alkanoate ester. These compounds, and, especially, agriculturally acceptable salts, esters, and amides of these compounds, were found to have herbicidal utility.

Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-b icyclo[2.2.1]heptanedicarboxime (Tandospirone) and related compounds

A series of cyclic imides bearing a ω-(4-aryl and 4-heteroaryl-1-piperazinyl)alkyl moieties was synthesized and tested in vivo for anxiolytic activity. The in vitro binding affinities of these compounds were also examined for 5-HT(1A) receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (1: tandospirone), was found to be equipotent with buspirone in its anxiolytic activity and more anxio-selective than buspirone and diazepam. Tandospirone (1) is currently undergoing clinical evaluation as a selective anxiolytic agent.